Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus

Clinical Rheumatology

Volumn 18, Issue 1, 1999, Pages 17-22

  Davas, E M ^a   Tsirogianni, A ^a   Kappou, I ^a   Karamitsos, D ^a   Economidou, I ^a   Dantis, P C ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Interleukin 6; Soluble receptor interleukin 2; Soluble receptors of TNF ; Systemic lupus erythematosus; Tumour necrosis factor

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPLEMENT HEMOLYSIS TEST; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033005853     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670050045     Document Type: Article

References (31)

1. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand black white mice: enhanced gene expression and acceleration of renal injury. J Immunol 1989;143:3470-5.
2. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1b gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988;141:3050-4.
3. Vissers MCM, Fontone JC, Wiggins R, Kunkel SL. Glomerular basement membrane-containing immune complexes stimulate tumor necrosis factor and interleukin-1 production by human monocytes. Am J Pathol 1989;134:1-6.
4. Jacob CO, McDevitt HO. Tumor necrosis factor a in murine 'autoimmune' lupus nephritis. Nature 1988;331:356-8.
5. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of TNFa causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-7.
6. Seckinger P, Isaay S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor. J Biol Chem 1989;264:11966-73.
7. Nophar Y, Kemprer O, Brakebusch C, Englemann H, Zwang R, Aderka D, et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs): the cDNA for the type I TNF-R, cloned using aminoacid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990;9:3269-78.
8. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified form human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265:1531-42.
9. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80.
10. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
11. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in excessive B cell function in patients with SLE. J Immunol 1993;151:6525-34.
12. Heinrich PC, Castell JV, Andus T. Interleukin-6 acute phase response. Biochem J 1990;91:1351-7.
13. Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982;8:91-101.
14. Gabay C, Roux-Lombard P, De Moerloose P, Dayer JM. Absence of correlation between interleukin-6 and C-reactive protein blood levels in SLE compared with rheumatoid arthritis. J Rheumatol 1993;20:815-21.
15. Spronk PE, TerBorg EJ, Limburg PC, Kallenberg CGM. Plasma concentration of IL-6 in SLE: an indicator of disease activity? Clin Exp Immunol 1992;90:106-10.
16. Tan EM, Cohen AS, Fries JF, Masi AT, AcShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Bencivelli W, Vitali C, Isenberg DA. Disease activity in SLE: report of the consensus study group of the European workshop for rheumatology research III. Development of a computerized clinical chart and its application in comparison of different indices of disease activity: the European consensus study group for disease activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
18. Bombardier C, Gladman DP, Urowitz MB, Karon D, Chang CH, and the Committee on Prognosis studies in SLE. Derivation of SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
19. Cope AP, Aderka D, Wallach D, Kahan M, Chu NR, Bremman FM. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 1995;84:21-30.
20. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy of tumor necrosis factor (TNF) clearance in a murine model. J Immunol 1993;150:2007-17.
21. Rubin LA. The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum 1990;33:1145-7.
22. Aderka O, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
23. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
24. Gabay G, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8.
25. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:146-50.
26. Campen DH, Horwitz DA, Quismorio FP, Ehresmann GR, Martin WJ. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988;31:1358-64.
27. Wolf RE, Brelsford WG.Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988;31:729-35.
28. Manousakis MN, Papadopoulos GK, Drosos AA. Moutsopoulos HM. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune disease. Clin Immunol Immunopathol 1989;50:321-32.
29. Ter Borg EJ, Horst G, Limburg PC, Kallenberg CGM. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbation and levels of anti-dsDNA and complement in SLE. Clin Exp Immunol 1990;82:21-6.
30. Riazziuddin S, Al-Janadi MA, Al-Wabel AA, Soluble interleukin-2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus. J Rheumatol 1991;18:831-6.
31. Laut J, Senitzer D, Petrucci R, Sablay LB, Barland P, Gricklich D. Soluble interleukin-2 receptor levels in lupus nephritis. Clin Nephrol 1992;38:179-84.